SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 2, 2026

IMNM

Immunome Inc.
BEARISH
Impact 5/10
Horizonweeks Processed4mo ago
Insider cluster: 2 insiders, $2.9M total
Actionable Insight ▼ Bearish

Insider selling is consistent across multiple insiders but modest relative to market cap, the selling is likely not a material signal of deterioration. Monitor for any negative pipeline updates or upcoming financing events.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.61
T+0 close · Jul 2, 2026 · via day close
Latest settled
−8.17%
T+60 · $21.68
Vs SPY
−11.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $23.61entry
  2. T+1 · 4mo ago +1.23%α +0.36% · $23.90
  3. T+5 · 4mo ago +2.37%α +1.44% · $24.17
  4. T+20 · 4mo ago −2.24%α −1.83% · $23.08
  5. T+60 · 7w ago −8.17%α −11.74% · $21.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Isaac Barchas and CMO Robert Lechleider sold a combined $2.93M in open-market sales over a week, with Barchas alone accounting for $2.13M. The cluster is entirely selling, and the total value (~0.12% of $2.4B market cap) is modest. Historical insider activity shows $6.6M in selling over 30 days, continuing this pattern.

Key Financial Metrics

Direction
selling
Total Value
$2.9M
Insiders
2

Key Facts

  • Director Barchas sold 76k shares at $22.35 on 7/2, 24k at $23.33 on 7/2, and 101k at $21.12 on 6/30; total Barchas sales = $4.39M across the cluster window
  • CMO Lechleider sold 41k shares at $19.56 for $794k
  • Cluster total: $2.93M in open-market sales; prior-30d insider selling totaled $6.6M
  • No insider buying in the cluster, net direction is selling
  • Market cap is $2.4B; cluster value is ~0.12% of market cap, below the 0.5% materiality threshold for outsized significance

Financial Impact

Total insider sales of $2.93M in this cluster (~0.12% of market cap), with $4.39M from the director alone.

insider sellingownershipshare supply

Risk Factors

  • Continued insider selling without buying could signal unstated concerns
  • Biotech sector: any pipeline setback would compound selling pressure
  • Historical stock drift has been negative after most filings; the pattern is bearish

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IMNM-1783038756017

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026